X4 Pharmaceuticals: Deep Track reports 6.58% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
X4 Pharmaceuticals, Inc. (XFOR) shares are reported as beneficially owned by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and David Kroin, who may be considered a control person of Deep Track Capital. As of September 30, 2026, Deep Track Capital and Kroin each reported beneficial ownership of 6,663,821 shares (6.58%), with shared voting and dispositive power. The Master Fund reported 5,737,941 shares (5.66%), and Special Opportunities reported 925,880 shares (0.91%). The reported totals include 2,162,137 pre-funded warrants exercisable for common stock, subject to a 9.99% maximum exercise limitation.
Key Figures
Key Terms
beneficially owned regulatory
Pre-Funded Warrants financial
Maximum Percentage regulatory
joint filing statement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much XFOR stock did Deep Track report beneficially owning?
What limit applies to the XFOR pre-funded warrants?
AI-generated analysis. How Rhea-AI works. Not financial advice.